ClinicalTrials.gg
CompletedNCT03515538PREVLARUpdated Nov 4, 2024Results posted

Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers

A Phase 2 interventional study of RRx-001 and Cisplatin for injection in Oral Mucositis, sponsored by EpicentRx, Inc.. Completed at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-04.

Sponsored by EpicentRx, Inc. · Phase 2, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
53
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies in Stomatitis with a site in United States — 12 open to participants now, 15 under way, none of them phase 3. Stomatitis · United States.

Enrollment
40th of 73
53 · median 60
Started
2018
with 7 others
Phase 2
33 of 80
2 open now
Registered
55th of 80
by date
Lead sponsor
2 of 80
EpicentRx, Inc.

Among the 80 studies in Stomatitis with a site in United States, this one is the 40th largest by enrollment of the 73 interventional ones that give a count, is one of 8 that started in 2018, is one of 33 in phase 2, and was the 55th registered.

Stomatitis

307 studies on the registry are indexed under Stomatitis; 74 are open to participants now.

Browse Stomatitis studies →

Open to participants now

12 of the 80 studies in Stomatitis with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 45 Stomatitis studies recruiting now, 20 (44%) set no upper age limit and 21 (47%) stop at 75 or younger; 10 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Stomatitis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the duration or length of severe oral mucositis in patients with head and neck cancers. All patients in this study will receive 7 weeks of standard of care radiation therapy given with the chemotherapy agent, cisplatin. Patients in arms 1, 2 and 3 will also receive RRx-001 on different schedules.

Read the detailed description

The standard treatment for head and neck cancer currently includes a chemotherapy drug called cisplatin that is given by intravenous (IV) infusion and radiation, which is delivered from a machine that precisely targets the tumor. One common and unfortunate side effect of treatment with cisplatin and radiation is oral mucositis, which refers to irritation of the lining of the mouth. Oral mucositis is a serious problem 1) because the open mouth sores from oral mucositis may lead to severe pain, nutritional problems and dehydration from an inability to eat and drink, an increased risk of infection from bacteria and fungus and delay or discontinuation of treatment and 2) because there is only one approved therapy to treat or prevent it.

03

Conditions studied

  • Oral Mucositis

Keywords

  • head and neck cancer
  • squamous
  • neck cancer
  • oral cancer
  • mucositis
  • sores
  • mouth
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed diagnosis of squamous cell carcinoma (SCC) of the oral cavity and oropharynx Note: Patients with unknown primary tumors whose treatment plan matches the requirements specified in Inclusion Criterion #3 below are eligible for the trial
  2. Treatment planned to include standard cisplatin monotherapy administered either every three weeks (100 mg/m2 for 3 doses) with concomitant radiation delivered as a continuous course of IMRT with single daily fractions of 2.0 to 2.2 Gy with a cumulative radiation dose between 60 Gy and 72 Gy. Planned radiation treatment fields must include at least two oral sites (buccal mucosa, floor of mouth, tongue, soft palate) that are each planned to receive a total of > 55 Gy. Patients who have had prior surgery are eligible, provided they have fully recovered from surgery, and patients who may have surgery in the future are eligible.
  3. performance status ≤ 2.
  4. Participants must have adequate organ and marrow function as defined below:

    A. (ANC) >1,500 / mm3 B. > 100,000 / mm3 C. ≥ 9.0 g/dL

  5. Adequate renal and liver function as indicated by:

    A. Serum creatinine acceptable for treatment with cisplatin per institutional guidelines) B. Total ≤ 1.5 x upper-normal limit () C. (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN D. Alkaline phosphatase ≤ 2.5 x ULN

  6. Human papilloma virus (HPV) status in tumor has been documented using tumor immunohistochemistry for HPV-p16 or other accepted test for patients with cancers of the oropharynx, base of tongue, or unknown primary.
  7. Age 18 years or older
  8. Patient must consent to the access, review and analysis of previous medical and cancer history, including imaging data by the sponsor or a third party nominated by the sponsor.
  9. Ability to understand and sign a written document.
  10. Women of and men with partners of child-bearing potential must agree to use adequate (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy.

    Note: A woman of child-bearing potential is any female (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:

    • Has not undergone a hysterectomy or bilateral oophorectomy; or
    • Has not been for at least 12 consecutive months
  11. Adequate visual access to permit examination of the following oral cavity sites: lips, buccal mucosa, floor of mouth, ventral and lateral tongue and soft palate.

Exclusion criteria

Exclusion Criteria:

  1. Prior radiation to the head and neck
  2. Tumor of the lips, nasopharynx, hypopharynx, larynx, or salivary glands
  3. Patients with simultaneous primaries or bilateral tumors
  4. disease (M1) Stage IV
  5. Malignant tumors other than HNC within the last 5 years, unless treated definitively and with low risk of recurrence in the judgment of the treating investigator
  6. Presence of oral mucositis (WHO Score ≥ Grade 1) or other oral mucosal ulceration at study entry
  7. Grade 3 or 4 dysphagia or odynophagia (National Cancer Institute Common Toxicity Criteria, version 5.0) or inability to eat a normal diet
  8. Requirement at baseline for parenteral or gastrointestinal tube-delivered nutrition for any reason
  9. Known history of or active /C (patients who have been vaccinated for hepatitis B and do not have a history of infection are eligible)
  10. Any significant medical diseases or conditions, as assessed by the investigators and sponsor that would substantially increase the medical risks of participating in this study (i.e., uncontrolled diabetes, II-IV congestive heart failure, myocardial infarction within 6 months of study, severe chronic pulmonary disease or active uncontrolled infection, uncontrolled or pulmonary edema).
  11. Pregnant or nursing
  12. Untreated active oral or dental infection, including severe tooth decay (caries)
  13. Known allergies or intolerance to cisplatin and similar platinum-containing compounds
  14. Evidence of immediate life-threatening disease or a of less than 3 months
  15. Receipt of unapproved or off-label medication within 30 days prior to start of study treatment
  16. Sjogren syndrome
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    RRx-001 Pre-Treatment plus SOC

    Two infusions of RRx-001 will be given each week during the two weeks prior to the start of RT/cisplatin SOC (four doses total). No additional RRx-001 will be given during the course of RT/cisplatin

    Drug: RRx-001 · Drug: Cisplatin for injection · Radiation: Radiation Therapy

  • Experimental
    RRx-001 Pre-Treatment, 2 Concurrent Doses plus SOC

    Two infusions of RRx-001 will be given each week during the two weeks prior to the start of RT/cisplatin SOC. In addition, one dose of RRx-001 will be given on the last radiation day in each of weeks 2 and 5 during RT/cisplatin administration

    Drug: RRx-001 · Drug: Cisplatin for injection · Radiation: Radiation Therapy

  • Experimental
    RRx-001 Pre-Treatment, 6 Concurrent Doses plus SOC

    Two infusions of RRx-001 will be given each week during the two weeks prior to the start of RT/cisplatin SOC. In addition, one dose of RRx-001 will be given on the last radiation day of each of the first 6 weeks during RT/cisplatin administration

    Drug: RRx-001 · Drug: Cisplatin for injection · Radiation: Radiation Therapy

  • Active comparator
    Standard of Care

    No doses of RRx-001 will be administered. Patients assigned to this arm will receive only standard of care in the form of a 7-week course of fractionated radiation therapy concurrent with a high-dose cisplatin regimen (100 mg/m2 dose in each of RT weeks 1, 4, and 7).

    Drug: Cisplatin for injection · Radiation: Radiation Therapy

Interventions

  • RRx-001 for injection

  • DrugCisplatinStudies of CisplatinCisplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will receive 3 doses of cisplatin at 100 mg/m2 in accordance with applicable guidelines such as NCCN; however, these guidelines are not intended to supersede or replace institutional guidelines with respect to appropriate and necessary care for individual patients

  • RadiationRadiation Therapy

    Intensity Modulated Radiation Therapy (IMRT) in accordance with the American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for IMRT) is mandatory for this study

06

What researchers measure

Primary outcomes

  1. Duration of Severe Oral Mucositis (SOM)

    Duration in days of severe oral mucositis (SOM). Defined as oral mucositis grade 3 or 4 on the WHO Mucositis Grading Scale which comprises 5 grades: 0 = none, 1= oral soreness, erythema, 2 = oral erythema, ulcers, solid diet tolerated, 3 = oral ulcers, liquid diet only, and 4 = oral alimentation impossible. Severe Oral Mucositis duration is obtained by totaling the number of days a given patient experiences oral mucositis grade 3 or 4 during the randomized treatment period. Higher Severe Oral Mucositis duration numbers are indicative of worst outcomes. The total Severe Oral Mucositis duration for a given patient will range between 0 days and the maximum number of days the patient participated in the randomized treatment period.

    Time frame: From start of treatment through 28 days post treatment for up to 11 weeks from Start of Treatment

Secondary outcomes

  1. Time to Onset of Severe Oral Mucositis

    Time to onset of Severe Oral Mucositis defined as time (in days) from randomization to the first observed Severe Oral Mucositis. Longer Severe Oral Mucositis onset times are indicative of a better outcome. The time to onset of Severe Oral Mucositis for a given patient will range between 0 days and the maximum number of days the patient participated in the randomized treatment period.

    Time frame: Time from Day 1 to Oral Mucositis Onset (up to 8 weeks)

  2. Incidence of Severe Oral Mucositis

    Incidence of Severe Oral Mucositis defined as the number of patients who experienced a Severe Oral Mucositis grade 4 during the randomized treatment period.

    Time frame: Baseline through end of treatment (up to 11 weeks). Data collected every week.

  3. Opioid Use

    Opioid use from the time to onset (TTO) and duration of opioid use among patients who were not taking opioids at radiation start or who required a second opioid during active treatment.

    Time frame: Baseline through end of radiation treatment (through 8 weeks). Data collected every week.

07

Results

Posted Nov 4, 2024

Participant flow

Participant flow — Overall Study
MilestoneRRx-001 Pre-Treatment Plus SOCRRx-001 Pre-Treatment, 2 Concurrent Doses Plus SOCRRx-001 Pre-Treatment, 6 Concurrent Doses Plus SOCStandard of Care
Started14131313
Completed91098
Not completed5345
Withdrew: Lack of efficacy2020
Withdrew: Death0010
Withdrew: Protocol violation0001
Withdrew: Screen failure (baseline dropout)0100
Withdrew: Withdrawal by subject2213
Withdrew: Physician decision1001

Outcome measures

PrimaryDuration of Severe Oral Mucositis (SOM)

Duration in days of severe oral mucositis (SOM). Defined as oral mucositis grade 3 or 4 on the WHO Mucositis Grading Scale which comprises 5 grades: 0 = none, 1= oral soreness, erythema, 2 = oral erythema, ulcers, solid diet tolerated, 3 = oral ulcers, liquid diet only, and 4 = oral alimentation impossible. Severe Oral Mucositis duration is obtained by totaling the number of days a given patient experiences oral mucositis grade 3 or 4 during the randomized treatment period. Higher Severe Oral Mucositis duration numbers are indicative of worst outcomes. The total Severe Oral Mucositis duration for a given patient will range between 0 days and the maximum number of days the patient participated in the randomized treatment period.

Time frame:
From start of treatment through 28 days post treatment for up to 11 weeks from Start of Treatment
Reported as:
Mean · Days
Duration of Severe Oral Mucositis (SOM)
DaysRRx-001 Pre-Treatment Plus SOCRRx-001 Pre-Treatment, 2 Concurrent Doses Plus SOCRRx-001 Pre-Treatment, 6 Concurrent Doses Plus SOCStandard of Care
Duration of Severe Oral Mucositis (SOM)22.9 ± 19.0827.7 ± 23.7235.2 ± 28.8337.8 ± 29.33
SecondaryTime to Onset of Severe Oral Mucositis

Time to onset of Severe Oral Mucositis defined as time (in days) from randomization to the first observed Severe Oral Mucositis. Longer Severe Oral Mucositis onset times are indicative of a better outcome. The time to onset of Severe Oral Mucositis for a given patient will range between 0 days and the maximum number of days the patient participated in the randomized treatment period.

Time frame:
Time from Day 1 to Oral Mucositis Onset (up to 8 weeks)
Reported as:
Median · Days to Onset
Time to Onset of Severe Oral Mucositis
Days to OnsetRRx-001 Pre-Treatment Plus SOCRRx-001 Pre-Treatment, 2 Concurrent Doses Plus SOCRRx-001 Pre-Treatment, 6 Concurrent Doses Plus SOCStandard of Care
Time to Onset of Severe Oral Mucositis38 (26 to NA)33 (22 to NA)37 (22 to NA)26 (18 to NA)
SecondaryIncidence of Severe Oral Mucositis

Incidence of Severe Oral Mucositis defined as the number of patients who experienced a Severe Oral Mucositis grade 4 during the randomized treatment period.

Time frame:
Baseline through end of treatment (up to 11 weeks). Data collected every week.
Reported as:
Count of participants · Participants
Incidence of Severe Oral Mucositis
ParticipantsRRx-001 Pre-Treatment Plus SOCRRx-001 Pre-Treatment, 2 Concurrent Doses Plus SOCRRx-001 Pre-Treatment, 6 Concurrent Doses Plus SOCStandard of Care
Incidence of Severe Oral Mucositis0463
SecondaryOpioid Use

Opioid use from the time to onset (TTO) and duration of opioid use among patients who were not taking opioids at radiation start or who required a second opioid during active treatment.

Time frame:
Baseline through end of radiation treatment (through 8 weeks). Data collected every week.
Reported as:
Count of participants · Participants
Opioid Use
ParticipantsRRx-001 Pre-Treatment Plus SOCRRx-001 Pre-Treatment, 2 Concurrent Doses Plus SOCRRx-001 Pre-Treatment, 6 Concurrent Doses Plus SOCStandard of Care
Week 11001
Week 22012
Week 34224
Week 44224
Week 54234
Week 64234
Week 74234
Week 84245

Adverse events

Collected over Adverse Events were collected beginning at baseline through end of treatment (12 weeks). All-Cause Mortality was assessed up to 12 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RRx-001 Pre-Treatment Plus SOC0/12 (0%)4/12 (33.3%)9/12 (75%)
RRx-001 Pre-Treatment, 2 Concurrent Doses Plus SOC0/11 (0%)4/11 (36.4%)10/11 (90.9%)
RRx-001 Pre-Treatment, 6 Concurrent Doses Plus SOC1/13 (7.7%)6/13 (46.2%)12/13 (92.3%)
Standard of Care0/10 (0%)5/10 (50%)6/10 (60%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventRRx-001 Pre-Treatment Plus SOCRRx-001 Pre-Treatment, 2 Concurrent Doses Plus SOCRRx-001 Pre-Treatment, 6 Concurrent Doses Plus SOCStandard of Care
Acute kidney injuryRenal and urinary disorders0/123/110/130/10
Atrial fibrillationCardiac disorders0/120/110/131/10
NauseaGastrointestinal disorders1/121/110/131/10
VomitingGastrointestinal disorders1/120/110/131/10
Lung infectionInfections and infestations0/120/110/131/10
HypophosphataemiaMetabolism and nutrition disorders0/120/110/131/10
ColitisGastrointestinal disorders0/121/110/130/10
StomatitisGastrointestinal disorders0/121/111/130/10
Febrile neutropeniaBlood and lymphatic system disorders1/120/110/130/10
Atrial flutterCardiac disorders1/120/110/130/10
Most frequent other events
Showing 10 of 41
Most frequent other events
EventRRx-001 Pre-Treatment Plus SOCRRx-001 Pre-Treatment, 2 Concurrent Doses Plus SOCRRx-001 Pre-Treatment, 6 Concurrent Doses Plus SOCStandard of Care
Lymphocyte count decreasedInvestigations2/125/114/133/10
DysphagiaGastrointestinal disorders0/121/114/134/10
White blood cell count decreasedInvestigations2/124/112/131/10
Neutrophil count decreasedInvestigations1/123/114/130/10
NauseaGastrointestinal disorders1/121/111/132/10
Oral dysesthesiaGastrointestinal disorders0/120/111/132/10
VomitingGastrointestinal disorders1/120/111/132/10
Oropharyngeal painRespiratory, thoracic and mediastinal disorders2/121/111/132/10
HypertensionVascular disorders1/120/110/132/10
Acute kidney injuryRenal and urinary disorders0/122/110/130/10

Baseline characteristics

Safety Population comprises all subjects who are randomized and received at least 1 dose of study drug and will be used for all analyses of safety. Analysis is based on actual treatment group

Age, Continuous
Age, Continuous(years)RRx-001 Pre-Treatment Plus SOCRRx-001 Pre-Treatment, 2 Concurrent Doses Plus SOCRRx-001 Pre-Treatment, 6 Concurrent Doses Plus SOCStandard of CareTotal
Mean57.7 ± 11.1756.7 ± 7.6459 ± 11.9459.5 ± 6.058.2 ± 9.48
Sex: Female, Male
Sex: Female, Male(Participants)RRx-001 Pre-Treatment Plus SOCRRx-001 Pre-Treatment, 2 Concurrent Doses Plus SOCRRx-001 Pre-Treatment, 6 Concurrent Doses Plus SOCStandard of CareTotal
Female22116
Male10912940
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)RRx-001 Pre-Treatment Plus SOCRRx-001 Pre-Treatment, 2 Concurrent Doses Plus SOCRRx-001 Pre-Treatment, 6 Concurrent Doses Plus SOCStandard of CareTotal
Hispanic or Latino01012
Not Hispanic or Latino111013943
Unknown or Not Reported10001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RRx-001 Pre-Treatment Plus SOCRRx-001 Pre-Treatment, 2 Concurrent Doses Plus SOCRRx-001 Pre-Treatment, 6 Concurrent Doses Plus SOCStandard of CareTotal
Asian00112
Black or African American11013
White111012841
Region of Enrollment
Region of Enrollment(participants)RRx-001 Pre-Treatment Plus SOCRRx-001 Pre-Treatment, 2 Concurrent Doses Plus SOCRRx-001 Pre-Treatment, 6 Concurrent Doses Plus SOCStandard of CareTotal
United States1211131046
08

Study locations

12 sites
  • John Wayne Cancer Institute @ Providence St. John's Health Center
    Santa Monica, California 90401, United States
  • Centura Health Research Center
    Denver, Colorado 80210, United States
  • George Washington University
    Washington, District of Columbia 20037, United States
  • Florida Hospital
    Orlando, Florida 32804, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • East Carolina University
    Greenville, North Carolina 27834, United States
  • University of Cincinnati Medical Center
    Cincinnati, Ohio 45267, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Ballad Health
    Johnson City, Tennessee 37604, United States
  • Vanderbilt-Ingram Cancer Center
    Nashville, Tennessee 37232, United States
  • UT Southwestern
    Dallas, Texas 75390, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Oct 2019, 15 months.

Results were first posted in Nov 2024, 5 years after primary completion.

Of 39 phase 2 interventional studies under Stomatitis, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 48. This study's 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2018
First posted
May 3, 2018
StartActual
Jul 12, 2018
Primary completionActual
Oct 22, 2019
CompletionActual
Oct 8, 2020
Results first posted
Nov 4, 2024
Last update
Nov 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03515538
Lead sponsor
EpicentRx, Inc.
Collaborators
Prothex, Inc.
Responsible party
Sponsor
First posted
May 3, 2018
Start date
Jul 12, 2018
Primary completion
Oct 22, 2019
Completion
Oct 8, 2020
Results posted
Nov 4, 2024
Last update
Nov 4, 2024

Study contacts

Bryan Oronsky, MD, PhD
study director · EpicentRx, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: RRx-001

Start the discussion